BACKGROUND AND OBJECTIVES: Inflammation-induced atherosclerosis and enhanced susceptibility to infection are linked to immune dysfunction and account for an important part of mortality in hemodialysis patients. This 4-yr prospective study aimed to use cytokine proteomic determination for predicting cardiovascular and noncardiovascular mortality in hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Levels of 12 cytokines were measured using a proteomic biochip system in 134 patients who were on stable hemodialysis and compared with a control group of 150 healthy volunteers. Cox proportional hazards regression analysis was used to determine the relationship between cytokine and clinical outcome. RESULTS: A proinflammatory state characterized by decreased anti-/proinflammatory cytokine ratio was evidenced in hemodialysis patients compared with control subjects. After adjustment for age, gender, smoking, and high-sensitivity C-reactive protein levels, IL-6 and (IL-4+IL-10)/IL-6 ratio were associated with a significant and specific enhanced hazard ratio of cardiovascular mortality (hazard ratio 11.32 [95% confidence interval 2.52 to 50.90; P < 0.01] and hazard ratio 3.14 [95% confidence interval 1.20 to 8.22; P < 0.05], respectively, when comparing the third and first tertiles). It is interesting that (IL-4+IL-6+IL-10)/(IL-2+IFN-gamma) ratio, used as a marker of lymphocytes T helper subsets cytokine secretion, was associated only with noncardiovascular mortality (hazard ratio 4.93; 95% confidence interval 1.03 to 23.65; P < 0.05). CONCLUSION: Beyond the strong prediction of cardiovascular mortality by IL-6, determination of cytokine ratios can be useful to identify hemodialysis patients with increased noncardiovascular mortality risk.
BACKGROUND AND OBJECTIVES: Inflammation-induced atherosclerosis and enhanced susceptibility to infection are linked to immune dysfunction and account for an important part of mortality in hemodialysis patients. This 4-yr prospective study aimed to use cytokine proteomic determination for predicting cardiovascular and noncardiovascular mortality in hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Levels of 12 cytokines were measured using a proteomic biochip system in 134 patients who were on stable hemodialysis and compared with a control group of 150 healthy volunteers. Cox proportional hazards regression analysis was used to determine the relationship between cytokine and clinical outcome. RESULTS: A proinflammatory state characterized by decreased anti-/proinflammatory cytokine ratio was evidenced in hemodialysis patients compared with control subjects. After adjustment for age, gender, smoking, and high-sensitivity C-reactive protein levels, IL-6 and (IL-4+IL-10)/IL-6 ratio were associated with a significant and specific enhanced hazard ratio of cardiovascular mortality (hazard ratio 11.32 [95% confidence interval 2.52 to 50.90; P < 0.01] and hazard ratio 3.14 [95% confidence interval 1.20 to 8.22; P < 0.05], respectively, when comparing the third and first tertiles). It is interesting that (IL-4+IL-6+IL-10)/(IL-2+IFN-gamma) ratio, used as a marker of lymphocytes T helper subsets cytokine secretion, was associated only with noncardiovascular mortality (hazard ratio 4.93; 95% confidence interval 1.03 to 23.65; P < 0.05). CONCLUSION: Beyond the strong prediction of cardiovascular mortality by IL-6, determination of cytokine ratios can be useful to identify hemodialysis patients with increased noncardiovascular mortality risk.
Authors: M Bhaskaran; R Ranjan; H Shah; J Siu; R Colvin; N Radhakrishnan; K Reddy; N Franki; J D Wagner; P C Singhal Journal: Clin Nephrol Date: 2002-03 Impact factor: 0.975
Authors: Edith M Simmons; Jonathan Himmelfarb; M Tugrul Sezer; Glenn M Chertow; Ravindra L Mehta; Emil P Paganini; Sharon Soroko; Stephanie Freedman; Karen Becker; Daniel Spratt; Yu Shyr; T Alp Ikizler Journal: Kidney Int Date: 2004-04 Impact factor: 10.612
Authors: Guixiang Zhao; Terry D Etherton; Keith R Martin; Peter J Gillies; Sheila G West; Penny M Kris-Etherton Journal: Am J Clin Nutr Date: 2007-02 Impact factor: 7.045
Authors: T B Drüeke; T Nguyen Khoa; Z A Massy; V Witko-Sarsat; B Lacour; B Descamps-Latscha Journal: Kidney Int Suppl Date: 2001-02 Impact factor: 10.545
Authors: Christelle Machon; Simon Thezenas; Anne-Marie Dupuy; Eric Assenat; Françoise Michel; Emilie Mas; Pierre Senesse; Jean-Paul Cristol Journal: Support Care Cancer Date: 2012-03-28 Impact factor: 3.603
Authors: Mehdi Rambod; Rachelle Bross; Jennifer Zitterkoph; Deborah Benner; Juhi Pithia; Sara Colman; Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Am J Kidney Dis Date: 2008-12-13 Impact factor: 8.860
Authors: S Fabre; C Guisset; L Tatem; N Dossat; A M Dupuy; J D Cohen; J P Cristol; J P Daures; C Jorgensen Journal: Clin Exp Immunol Date: 2009-03 Impact factor: 4.330
Authors: S Fabre; A M Dupuy; N Dossat; C Guisset; J D Cohen; J P Cristol; J P Daures; C Jorgensen Journal: Clin Exp Immunol Date: 2008-06-18 Impact factor: 4.330
Authors: Mario Bonomini; Vittorio Sirolli; Luisa Pieroni; Paolo Felaco; Luigi Amoroso; Andrea Urbani Journal: Int J Mol Sci Date: 2015-12-10 Impact factor: 5.923
Authors: Stefanie Bünger; Ulrike Haug; Maria Kelly; Nicole Posorski; Katja Klempt-Giessing; Andrew Cartwright; Stephen P Fitzgerald; Vicki Toner; Damien McAleer; Timo Gemoll; Tilman Laubert; Jürgen Büning; Klaus Fellermann; Hans-Peter Bruch; Uwe J Roblick; Hermann Brenner; Ferdinand von Eggeling; Jens K Habermann Journal: BMC Cancer Date: 2012-09-07 Impact factor: 4.430